|
21 Jan 2020 |
Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease
|
|
21 Jan 2020 |
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
|
|
21 Jan 2020 |
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
|
|
21 Jan 2020 |
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
|
|
21 Jan 2020 |
Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody
|
|
21 Jan 2020 |
Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis
|
|
21 Jan 2020 |
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
|
|
21 Jan 2020 |
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical
|
|
21 Jan 2020 |
European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
|
|
21 Jan 2020 |
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
|
|
21 Jan 2020 |
HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic
|
|
20 Jan 2020 |
Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early
|
|
20 Jan 2020 |
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
|
|
20 Jan 2020 |
Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
|
20 Jan 2020 |
Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer
|
|
17 Jan 2020 |
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
|
|
17 Jan 2020 |
Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Disease
|
|
17 Jan 2020 |
Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est
|
|
17 Jan 2020 |
BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor
|
|
17 Jan 2020 |
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
|
